Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer Norvasc Challenges: Mylan ANDA, Dr. Reddy’s 505(b)(2)

Oct 21 2002

• By The Pink Sheet

Related Content

Bristol mail room mishap permitted Geneva generic captopril approval -- BMS testimony.

Dec 04 1995

Pfizer, Pharmacia Protest Inclusion Of Drug Innovator Data In "Paper NDAs"

Aug 20 2001

Generics With Poor Bioavailability May Not Use 505(b)(2) "Paper" NDA

Dec 13 1999

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window